Spark Therapeutics

In May 2014, Deerfield invested in Spark Therapeutics through a $72.8 million Series B financing. Spark is a private clinical stage gene therapy company based in Philadelphia, PA and spun out of the Children’s Hospital of Philadelphia (CHOP).

Spark is a leader in the gene therapy field with a Phase 3 program for inherited retinal dystrophies caused by mutations of the RPE65 gene. Proceeds from the financing will be utilized to complete the clinical development and regulatory process for the lead compound and advance the company’s pipeline in other inherited retinal dystrophies, hemophilia B and neurodegenerative diseases.